Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

United States

National Institute of Health Clinical Center, Bethesda, Maryland

Houston Methodist Neal Cancer Center, Houston, Texas

The University of Texas MD Anderson Cancer Center, Houston, Texas